whose devices were removed . | ||||
Professor Gilbert said , for | ||||
Ms Leggett , the end of the trial |
‘ If only one person benefits from a drug , do we build a factory to make that drug for one person ?’ |
would have been far smoother had the device failed to help end her seizures .
“ If some of the components had broken or the battery was leaking , Rita would have been covered by the insurance covering clinical trials .
“ But not the other way around .”
|
||||
— Professor Frédéric Gilbert |
‘ A part of me ’
For the case report ,
|
||||
Ms Leggett said she | ||||
was the last patient | ||||
from the trial to go | ||||
through the surgery to | ||||
remove her BCI . | ||||
“ My husband would | ||||
have taken a second mortgage | ||||
on our home for me | ||||
to keep it ,” she said . | ||||
“ They took away that part | ||||
of me that I could rely on . |
Rita Leggett . |
My confidence in myself was |
|||
shattered . |
||||||||||||||||||||
“ I do not go out much unless |
||||||||||||||||||||
I am with my husband . My social |
||||||||||||||||||||
life is non-existent now . |
||||||||||||||||||||
“ To finally switch off my |
||||||||||||||||||||
device was the beginning of a |
||||||||||||||||||||
mourning period for me — a feel- |
||||||||||||||||||||
work at all ,” he said . |
who felt they had benefited |
were legitimate questions over |
difficult ,” he said . |
ing like I had lost something pre- |
||||||||||||||||
“ There will inevitably be dis- |
could enrol in another BCI trial , |
who should be responsible for |
One suggestion was that BCI |
cious and dear to me that could |
||||||||||||||||
appointment for people for whom |
“ although there are some you |
patients with BCIs when trials |
companies should all contrib- |
never be replaced . |
||||||||||||||||
treatments of any kind work but |
cannot implant twice , in the |
ended . |
ute to a global fund , with bigger |
“ It was a part of me .” |
||||||||||||||||
|
same way you can only have your hip replaced a certain number of times ”.
Professor Gilbert said there
|
“ It should be the manufacturer that is responsible , but sometimes it is running low on financial support , so it is |
companies paying more to provide support to patients after trials ended to maintain devices or provide more care to patients |
Brain Stimul 2023 ; 1 May . Lancet Psychiatry 2017 ; 4 Oct . Lancet Neurol 2013 ; 2 May . |
||||||||||||||||